Ann: Webcast Today - New Data from bioMUSE Natural History Study, page-66

I listened with interest and suffered an initial feeling of dread when he spoke of introducing a new brain volume primary endpoint. It took me back to the meeting after their failed reach2 HD results came in. There was a measurable reduction on brain atrophy, but it was not an endpoint. I can recall some investors mocking a statement at that meeting, that if they had included brain volume as an endpoint, the trial would have been a success. Seems like they didn't need AI to measure brain volume back then. That drug was also a chelator. Some brain atrophy every year is normal, so even slowing atrophy to normal rate of decline may be enough.